Stanford University Medical Center — Biomedical Watch V2

Essais liés8clinical trials

VillePalo Altolocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07517263

Ouvrir le site du centre

Essais cliniques associés

8

Molécule	Indication / population	Phase	NCT	Titre	Statut
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL	Maladie coronarienne	Phase 3	NCT05739383	A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	ACTIVE_NOT_RECRUITING
JNJ-63733657	Alzheimer	Phase 2	NCT04619420	Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease	TERMINATED
Surgical management	Accident vasculaire cérébral	Non applicable	NCT06870812	REACH — Rapid Evacuation and Access of Cerebral Hemorrhage Trial	RECRUITING
Pelacarsen (TQJ230)	Accident vasculaire cérébral	Phase 3	NCT07517263	An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)	ACTIVE_NOT_RECRUITING
KYV-101 anti-CD19 CAR-T cell therapy	Lupus	Phase 1/2	NCT05938725	KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis	TERMINATED
ION363	Sclérose latérale amyotrophique	Phase 3	NCT04768972	FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)	ACTIVE_NOT_RECRUITING
Standard lymphodepletion regimen	Myasthénie	Phase 2/3	NCT06193889	KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis	RECRUITING
Interferon beta-1a	SEP	Phase 3	NCT01412333	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis	COMPLETED